NCT03317496 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT03317496
Title	Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies
Recruitment	Terminated
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Pfizer
Indications	lung non-small cell carcinoma transitional cell carcinoma urethra transitional cell carcinoma Advanced Solid Tumor ureter transitional cell carcinoma renal pelvis transitional cell carcinoma
Therapies	Avelumab + Cisplatin + Gemcitabine Avelumab + Carboplatin + Pemetrexed Disodium
Age Groups:	adult \| senior
Covered Countries	USA \| ITA \| HUN \| GBR \| ESP \| CZE \| CAN \| AUS

Additional content available in CKB BOOST